This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Licun, W. Articles by Tannock, I. F. Search for Related Content PubMed PubMed Citation Articles by Licun, W. Articles by Tannock, I. F.

Selective Estrogen Receptor Modulators as Inhibitors of Repopulation of Human Breast Cancer Cell Lines after Chemotherapy

Division of Experimental Therapeutics and Department of Medical Oncology and Hematology, Princess Margaret Hospital and University of Toronto, Toronto, Ontario M5G 2M9 Canada

Purpose: Repopulation of surviving tumor cells between courses of chemotherapy might lead to effective drug resistance. Here we study inhibition of repopulation of hormone-responsive human breast cancer cell lines by selective estrogen receptor (ER) modulators (SERMs) during courses of chemotherapy.

Experimental Design: Hormone responsive breast cancer cell lines MCF-7 and T47D, and the ER- cell line MDA-231, were treated with either 4-hydroxy tamoxifen (4OHT) or arzoxifene during weekly courses of treatment with 5-fluorouracil (5-FU) or methotrexate (MTX). Clonogenic assays were performed to determine the overall survival of tumor cells after treatment with the SERMs alone, after one to three doses of 5-FU or MTX alone, and after 5-FU or MTX followed by each of the SERMs.

Results: Both SERMs inhibited the growth of ER+ cells MCF-7 and T47D but had no effect on the ER-cell line MDA-231. Arzoxifene was more effective than 4OHT. Between courses of treatment with either 5-FU or MTX, repopulation of ER+ cells was specifically inhibited by the SERMs, whereas repopulation of ER- MDA-231 was not affected.

Conclusions: Arzoxifene and 4OHT can inhibit specifically the repopulation of ER+ breast cancer cells between courses of chemotherapy. Scheduling of short-acting SERMs between courses of chemotherapy has the potential to improve therapeutic index.

This article has been cited by other articles:

				L. Wu and I. F. Tannock Effect of the Selective Estrogen Receptor Modulator Arzoxifene on Repopulation of Hormone-Responsive Breast Cancer Xenografts between Courses of Chemotherapy Clin. Cancer Res., November 15, 2005; 11(22): 8195 - 8200. [Abstract] [Full Text] [PDF]

				L. Wu, D. C. Birle, and I. F. Tannock Effects of the Mammalian Target of Rapamycin Inhibitor CCI-779 Used Alone or with Chemotherapy on Human Prostate Cancer Cells and Xenografts Cancer Res., April 1, 2005; 65(7): 2825 - 2831. [Abstract] [Full Text] [PDF]

				I. F. Tannock Limited Drug Access and Repopulation of Surviving Tumor Cells between Courses of Chemotherapy: Important and Neglected Causes of Clinical Drug Resistance Am. Assoc. Cancer Res. Educ. Book, April 1, 2005; 2005(1): 103 - 107. [Full Text] [PDF]